Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial

Ophthalmology

Volumn 108, Issue 6, 2001, Pages 1023-1031

  Brandt, James D ^a,c   VanDenburgh, Amanda M ^b   Chen, Kuankuan ^b   Whitcup, Scott M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALLERGAN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BIMATOPROST; TIMOLOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYELASH; GLAUCOMA; HUMAN; HUMAN TISSUE; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA; HEMODYNAMIC PROCESSES; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; SAFETY; TIMOLOL; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELDS;

EID: 0034986538     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(01)00584-X     Document Type: Article

References (22)

1. 2α with a hydroxyl or methoxy substituent provides biologically unique compounds
2. 2 ethanolamide from anandamide by cyclooxygenase-2
3. Comparison of the Ocular Hypotensive Lipid™ AGN 192024 with timolol: Dosing, efficacy and safety evaluation of a novel compound for glaucoma management
4. Timolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucoma
5. Comparison of latanoprost and timolol in subjects with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States
6. Nonparametrics
7. Rank transformations as a bridge between parametric and nonparametric statistics
8. A useful testing strategy in phase III trials: Combined test of superiority and test of equivalence
9. Effects of systemic β-blocker therapy on the efficacy and safety of topical brimonidine and timolol
10. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in subjects with primary open-angle glaucoma or ocular hypertension
11. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects
12. Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: A five-year, randomized, double-masked, clinical trial
13. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol
14. A six month randomized double-masked study comparing latanoprost to timolol in open-angle glaucoma and ocular hypertension
15. Why do some people go blind from glaucoma?
16. Ocular beta-blockers and systemic effects
17. Antiglaucoma medications: A review of safety and tolerability issues related to their use
18. Shortterm "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents
19. Systemic side effects of topical beta-adrenergic blockers
20. Effects of AGN24, a new ocular hypotensive agent, on aqueous dynamics